Roquefort Therapeutics (LON:COIL) Posts Earnings Results

Roquefort Therapeutics (LON:COIL) posted its quarterly earnings data on Wednesday. The company reported GBX (2.19) earnings per share for the quarter, Digital Look Earnings reports. Roquefort Therapeutics had a negative return on equity of 18.30% and a negative net margin of 57,057.07%.

Roquefort Therapeutics Stock Up 6.7%

Shares of Roquefort Therapeutics stock traded up GBX 0.50 during trading on Wednesday, reaching GBX 8. The company’s stock had a trading volume of 2,363 shares, compared to its average volume of 154,688. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The company has a market cap of £34.07 million, a price-to-earnings ratio of -1.27 and a beta of 0.05. Roquefort Therapeutics has a 1-year low of GBX 6.75 and a 1-year high of GBX 10. The company has a 50-day simple moving average of GBX 9.17 and a two-hundred day simple moving average of GBX 12.82.

About Roquefort Therapeutics

Coiled Therapeutics (AIM: COIL) is an AIM-listed, clinical-stage biotechnology company focused on developing innovative precision oncology therapies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently in Phase I clinical trials in the USA (trials ID: NCT06136884). Coiled Therapeutics is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments. The Company is also assessing its STAT-6 siRNA programme for immunology indications.